clinical 1,552 words KG: Als
Contents

Intravenous Immunoglobulin (IVIG) in ALS Trial

No AI portrait yet

Knowledge Graph

Agent Input

Related Hypotheses (130)

RAB27A-dependent extracellular vesicle engineering for mitoc
Score: 0.67
Metabolic Reprogramming via Microglial Glycolysis Inhibition
Score: 0.67
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.67
RNA Granule Nucleation Site Modulation
Score: 0.66
Optogenetic Microglial Deactivation via Engineered Inhibitor
Score: 0.66
Arginine Methylation Enhancement Therapy
Score: 0.65
Nucleolar Stress Response Normalization
Score: 0.65
DNMT1-Targeting Antisense Oligonucleotide Reset
Score: 0.65
Mitochondrial SPM Synthesis Platform Engineering
Score: 0.65
Synthetic Biology Rewiring via Orthogonal Receptors
Score: 0.65
FOXO3-Longevity Pathway Epigenetic Reprogramming
Score: 0.63
Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro
Score: 0.61
The Glial Ketone Metabolic Shunt Hypothesis
Score: 0.61
Extracellular Vesicle Biogenesis Modulation
Score: 0.58
Fractalkine Axis Amplification via CX3CR1 Positive Allosteri
Score: 0.56
Circadian-Gated Maresin Biosynthesis Amplification
Score: 0.56
Liquid-Liquid Phase Separation Modifier Therapy
Score: 0.55
Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy
Score: 0.55
HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor
Score: 0.54
Temporal Decoupling via Circadian Clock Reset
Score: 0.54
← Prevpg 3/7Next →

Related Analyses (17)

TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed

Related Experiments (30)

Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40

See Also (2)

A2M Gene
gene · KG edge: interacts_with
ABCA1 - ATP-Binding Cassette Transporter A1
gene · KG edge: activates

Knowledge Graph (12 edges)

ASC therapeutic_target Als
NAIP activates Als
SOAT1 expressed_in Als
LIPA expressed_in Als
NPC2 expressed_in Als
IRS1 contributes_to Als
Insulin Receptor contributes_to Als
IGF-1 therapeutic_target Als
Insulin Receptor therapeutic_target Als
Als contributes_to Cgas-Sting

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...